Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children

GlaxoSmithKlineA simple low-cost device that helps newborn babies to breathe and has the potential to transform the life chances for thousands of African babies has been awarded the highest fund in the first GSK and Save the Children $1 million Healthcare Innovation Award.

The life-saving kit, called a 'bubble' Continuous Positive Airway Pressure, or 'bCPAP', is used to help babies in respiratory distress, which is often caused by acute respiratory infections like pneumonia. CPAP devices use air pressure to keep patients airways open, and as there are few wall-mounted air supplies in Malawi hospitals, the newly innovated bCPAP air pump works on its own. Plus it is made of durable materials that are inexpensive and easy to repair. A similar version is already commonly used in developed countries where they cost at least $6,000 each. This innovative low-cost 'bubble' CPAP adaptation can be produced for approximately $400.

The organisation behind the innovation and recipients of a $400,000 share of the $1 million award is Friends of Sick Children, Malawi - a partnership between the paediatric department of Queen Elizabeth Central Hospital in Blantyre, Malawi, Rice 360°: Institute for Global Health Technologies in the United States and the University of Malawi College of Medicine. The funding from the Healthcare Innovation Award, along with backing from the Ministry of Health in Malawi, will mean use of the device can be replicated and expanded to Tanzania, Zambia and South Africa.

A judging panel of experts from the fields of public health and development, co-chaired by Sir Andrew Witty, CEO of GSK, and Justin Forsyth, Chief Executive of Save the Children, were impressed with the bCPAP device’s impact on tackling newborn deaths, and the associated comprehensive training and education programme on premature child-care. Newborn mortality rates continue to be a challenge in the developing world and in 2012, three million babies died in their first 28 days of life.

The bCPAP device was one of five projects, from a long list of nearly 100 applications from 29 countries across the developing world, selected by the judging panel.

Sir Andrew Witty, CEO of GSK, said: "Through this initiative, we have seen a wealth of creativity and innovation to better serve children's health needs in developing countries. I want to pay tribute to the ingenuity of all the organisations who applied for the award.

"These remarkable projects show that significant numbers of lives can be saved and improved through grass-roots innovation. We hope our awards will help 'spread the word' on many of these innovations and encourage others to use and learn from them."

Justin Forsyth, Chief Executive Save the Children, said: "Despite huge progress being made in under-five mortality in the past ten years, there hasn't been the same progress made in the number of newborn babies dying in poor countries in the first 28 days of life. This is an area that needs urgent attention, so it is heartening that all five winning innovations from this award concentrate on the area of newborn care. It is also inspiring to see countries finding solutions to their own challenges and partnering with other countries in the developing world to replicate and champion new innovations."

The Friends of Sick Children, Malawi and the bCPAP team said: "We are delighted to be the recipients of the first GSK-Save the Children Healthcare Innovation Award. The award money will help us to replicate and begin scaling up our programme across Africa and will make sure that we are reaching and saving even more children's lives. To be recognised for the work that we do and to hopefully inspire others around the world is an honour."

Four other organisations apportioned grants from the $1 million fund were:

  • BRAC, Bangladesh - $300,000 awarded for the 'Manoshi' programme, which delivers a comprehensive package of health services for women and children in the urban slums of Dhaka
  • MUSO, Mali - $100,000 awarded for focus on a community-level system designed to support the early identification of women and children in need of healthcare, before their symptoms escalate to a more serious condition
  • Microclinic Technologies, Kenya - $100,000 awarded for an innovative mobile health management system designed to improve the quality of maternal and child care by providing access to real-time data to improve health planning decisions
  • Kangaroo Foundation, Colombia (Fundacion Canguro) - $100,000 awarded in special recognition of their long-term Kangaroo Mother Care programme, which promotes early skin-to-skin contact between mothers and their premature and newborn babies.

The partnership between GSK and Save the Children aims to deliver a new model for corporate-charity working to help save the lives of a million children.

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Save the Children - works in more than 120 countries. We save children's lives. We fight for their rights. We help them fulfil their potential.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...